Clinical Scorecard: Identification of Latent Tuberculosis Infection in Heart Transplant Candidates and Recipients Before and After Surgery

At a Glance

Key Highlights

• LTBI prevalence in heart transplant recipients is 53.6%, significantly higher than in healthy controls (5.8%).
• Pre-transplant patients show a 35.7% LTBI prevalence, also significantly exceeding controls.
• Both patient groups exhibit higher LTBI rates due to immune dysregulation from chronic heart failure and immunosuppressive therapy.
• Routine LTBI screening and preventive therapy are critical in this population.
• The study emphasizes the need for optimized pre-transplant screening strategies.

Guideline-Based Recommendations

Diagnosis

• Systematic screening for LTBI in organ transplant candidates using modern immunodiagnostic methods.

Management

• Initiation of preventive therapy for LTBI to reduce the risk of active tuberculosis.

Monitoring & Follow-up

• Regular assessment of LTBI status in heart transplant candidates and recipients.

Risks

• Increased risk of active tuberculosis due to immunosuppressive therapy and reactivation of LTBI.

Patient & Prescribing Data

Patients awaiting heart transplantation and heart transplant recipients.

Management of LTBI is complicated by drug interactions with immunosuppressive agents.

Clinical Best Practices

• Conduct comprehensive immunological testing for LTBI in heart transplant candidates.
• Implement routine LTBI screening protocols in transplant centers.
• Educate patients about the risks of tuberculosis post-transplant.

Related Resources & Content

• World Health Organization guidelines